R-006

リスペリドン 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

• 実験式（ヒル表記法）: C₂₃H₂₇FN₄O₂
• CAS番号: 106266-06-2
• 分子量: 410.48
• UNSPSCコード: 41116107
• NACRES: NA.24

特性

• グレード: certified reference material
• 形状: liquid
• 特徴: Snap-N-Spike^®/Snap-N-Shoot^®
• 包装: ampule of 1 mL
• メーカー／製品名: Cerilliant^®
• 濃度: 1.0 mg/mL in methanol
• テクニック: gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• アプリケーション: clinical testing
• フォーマット: single component solution
• 保管温度: −20°C
• SMILES記法: CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1
• InChI: 1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
• InChI Key: RAPZEAPATHNIPO-UHFFFAOYSA-N
• 遺伝子情報: human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)

詳細

詳細

リスパダール^®、Ridal、またはRiscalinとして市販されているリスペリドンは、統合失調症、双極性障害、および自閉症児の易刺激性の治療に使用される非定型抗精神病薬です。この新しい認定済みSnap-N-Spike^® 溶液は、法医学分析、臨床毒性学、または尿中薬物検査など多くのLC/MSおよびGC/MS用途に適しています。

アプリケーション

• Vascular Syndromes and Neuroleptic Therapy: RisperiDonesolution has been investigated for its role in inducing severe vascular occlusion-like syndromes in rat models. Research highlights its potential implications for understanding drug-induced vascular problems and testing therapies like BPC 157, a gastric pentadecapeptide with promising therapeutic effects (Strbe et al., 2023).


• UHPLC Method Development: RisperiDoneis a focal point in the development of an advanced UHPLC method using the "Method Operable Design Region" (MODR) approach. This method is designed for the assay and purity determination of risperiDonein various formulations, crucial for maintaining stringent quality controls in pharmaceutical manufacturing (Pawar et al., 2022).


• Optimizing Antipsychotic Dose Regimens: Research incorporates risperiDoneto explore Maximum A Posteriori (MAP) Bayesian modelling, merging drug plasma concentrations and dopamine receptor occupancy. This approach aims to customize antipsychotic dosing to enhance therapeutic outcomes in individual patients, emphasizing personalized medicine in psychiatry (Ismail et al., 2022).


• Antioxidant-mediated Drug Degradation: Studies on risperiDonealso cover the formulation aspects, such as its inclusion in poly(ethylene carbonate) systems to control drug degradation through antioxidant mediation. This research is pivotal in developing sustained-release formulations that enhance drug stability and efficacy (Bohr et al., 2020).


• Patient-reported Outcomes in Schizophrenia Treatment: RisperiDonesolution is studied for its effectiveness in treating schizophrenia, particularly assessing patient-reported outcomes in long-term therapy settings. This research helps gauge patient satisfaction and treatment efficacy, which is essential for optimizing mental health therapies (Dhanda et al., 2019).

法的情報

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Risperdal is a registered trademark of Johnson & Johnson

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

安全性情報

• ピクトグラム: GHS02,GHS06,GHS08
• シグナルワード: Danger
• 危険有害性情報: H225,H301 + H311 + H331,H370
• 注意書き: P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311
• 危険有害性の分類: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• ターゲットの組織: Eyes,Central nervous system
• 保管分類コード: 3 - Flammable liquids
• WGK: WGK 2
• 引火点(°F): 49.5 °F - closed cup
• 引火点(℃): 9.7 °C - closed cup